CELDARA MEDICAL

CM-PW4: Translating a Validated Influenza Antibody for Feline Health

A first-in-class feline/human chimeric monoclonal antibody built on a well characterized, broadly neutralizing anti-influenza antibody, developed through Celdara Medical's One Health model.

Asset	Parent Antibody	Intended Use
CM-PW4 - feline/human chimeric monoclonal antibody	A human anti-influenza mAb targeting the hemagglutinin stalk	Influenza prevention and post-exposure treatment in cats
Status	**Parent Data**	**Next Milestone**
Construct is engineered, characterization & in vitro neutralization underway	90% survival, one dose, 72 hrs after lethal H5N1 challenge in mice	CM-PW4 neutralization in feline cells, Q1 2027

Seeking: Animal health partner for license and/or co-development

Need	H5N1 kills up to 70% of infected cats, and contaminated raw food carries it directly into the home. No H5N1-specific intervention for cats is approved; care today is off-label oseltamivir and supportive care.
Why CM-PW4	Designed to neutralize the virus directly, as a single dose before or after exposure. Pairs the validated human binding region with a feline backbone for use in cats, with a path to other companion and zoo species.
Evidence	All in vivo data to date is from the human parental antibody. We observed 80-100% survival against H7N9, and 87% survival against oseltamivir resistant H1N1. No tissue cross reactivity was observed. Feline in vitro studies are funded.
Commercial Model	Early adopters include owners of raw-fed and outdoor cats, shelters in affected regions, specialty hospitals and zoos. One product serves both routine prevention in high-risk cats and urgent treatment after exposure.
Team & IP	Developed in collaboration with Drs. Gary Whittaker and Patrick Wilson. Parental antibody covered by granted US patent, exclusively licensed from UChicago; improvements covered by trade secrets. More than $6.1M currently invested.

Years of human-program investment
Ready for veterinary development
Full data package available under CDA

Stephanie Mack, PhD
stephanie.mack@celdaramedical.com